For American parents, particularly those with young children, the past couple of months have been dizzying and beyond frustrating.
In early February, federal regulators announced they would evaluate Pfizer-BioNTech¡¯s coronavirus vaccine for the youngest children ¡ª only to scrap that plan 10 days later, citing doubts about the vaccine¡¯s effectiveness in that age group.
Soon after, scientists reported that the vaccine was only weakly protective against infection with the omicron variant among children ages 5 to 11 and that it appeared to offer little defense against moderate COVID-19 illness among adolescents ages 12 to 17.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.